ArticleInternational journal of urology : official journal of the Japanese Urological Association2025
Patient Preferences for Post-Radical Cystectomy Treatment in Muscle-Invasive Bladder Cancer: A Discrete Choice Experiment in Japan.
Article in International journal of urology : official journal of the Japanese Urological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genotoxicity of cancer therapies and the risk of secondary malignancies: toward personalized prevention.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
- Safety of Robot-Assisted Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Real-World Analysis Using the National Clinical Database in Japan.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectivesThis study aimed to assess the treatment preferences of Japanese patients with muscle-invasive bladder cancer (MIBC) by quantifying their trade-offs between treatment attributes using a discrete choice experiment (DCE).
methodsA DCE was conducted among MIBC patients post-radical cystectomy. Participants were presented with hypothetical treatment options differing in attributes such as efficacy Disease-free survival (DFS), side effects, administration, and cost. Preference data were analyzed to determine each attribute's relative importance (RI), maximum acceptable risk (MAR), and willingness to trade efficacy (WTTE).
resultsOut of 105 patients surveyed, 101 were included in the final analysis. The DCE revealed that DFS had the highest RI (30.3%), followed by annual treatment cost (27.7%) and risk of severe side effects (26.8%). While MAR analysis indicated that patients were willing to accept some increase in side effects risk for significant gains in DFS, WTTE results showed a sensitivity to side effect severity and treatment costs, with patients often willing to trade off DFS for improvements in risks and costs. In subgroup analyses, such as pathological stage, age, and employment status, the trends for each subgroup were the same as those of the overall population. However, the magnitude of RI varied among patients with different characteristics. For example, younger patients preferred short-term treatment duration over longer, employed patients tended to favor long-term treatment duration.
conclusionsThis study is the first to demonstrate the treatment preferences of Japanese MIBC patients who underwent radical cystectomy, and these results can inform treatment selection based on patient preferences.
trial registrationJapan Registry of Clinical Trials: jRCT1030220680.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.